Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure

Health Technology Assessment

Volumn 7, Issue 2, 2003, Pages

  Mowatt, G ^a   Vale, L ^a,b   Perez, J ^b   Wyness, L ^a   Fraser, C ^a   MacLeod, A ^b,c   Daly, C ^b,c   Stearns, S C ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c NHS GRAMPIAN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BIOMEDICAL TECHNOLOGY ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; HEMODIALYSIS; HOME CARE; HOSPITAL CARE; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; PATIENT SATISFACTION; PATIENT TRANSPORT; PERITONEAL DIALYSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; VALIDATION PROCESS; CHRONIC KIDNEY FAILURE; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; HOME DIALYSIS; PATIENT SELECTION; UNITED KINGDOM; UTILIZATION REVIEW;

COST-BENEFIT ANALYSIS; GREAT BRITAIN; HEALTH CARE COSTS; HEMODIALYSIS UNITS, HOSPITAL; HEMODIALYSIS, HOME; HUMANS; KIDNEY FAILURE, CHRONIC; PATIENT SELECTION; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 0038205488     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta7020     Document Type: Review

References (64)

1. Khan IH, Campbell MK, Cantarovich D, Catto GR, Delcroix C, Edward N, et al. Comparing outcomes in renal replacement therapy: How should we correct for case mix? Am J Kidney Dis 1998;31:473-8.
2. MacLeod A, Grant A, Donaldson C, Khan I, Campbell M, Daly C, et al. Effectiveness and efficiency of methods of dialysis therapy for end-stage renal disease: Systematic reviews. Health Technol Assess 1998;2(5).
3. Willis N, Craig J, Dury S, Mitchell R. Cochrane Renal Group. In: The Cochrane Library. Issue 5. Oxford: Update Software; 2001.
4. UK Renal Registry. Annual Report. Bristol, UK: The UK Renal Registry; 2000.
5. Scottish Renal Registry. Annual Report. Edinburgh, UK: Common Service Agency, Information and Statistics Division; 2001.
6. UK Renal Registry. Annual Report. Bristol, UK: The UK Renal Registry; 1999.
7. Oxman AD, Guyatt GH. The science of reviewing research. Ann NY Acad Sci 1993;703:125-33.
8. Drey N, Armitage A, Greenwood R, Feest T, Lamping D, Roderick P. Improving access to dialysis care: A national survey of renal satellite units in England and Wales (unpublished). Southampton, UK: Health Care Research Unit, University of Southampton; 2002.
9. Oxman AD. Checklists for review articles. BMJ 1994;309:648-51.
10. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998;52:377-84.
11. Jacobs C, Selwood NH. Renal replacement therapy for end-stage renal failure in France: Current status and evolutive trends over the last decade. Am J Kidney Dis 1995;25:188-95.
12. Mohr PE, Neumann PJ, Franco SJ, Marainen J, Lockridge R, Ting G. The case for daily dialysis: Its impact on costs and quality of life. Am J Kidney Dis 2001;37:777-89.
13. Cameron JI, Whiteside C, Katz J, Devins GM. Differences in quality of life across renal replacement therapies: A meta-analytic comparison. Am J Kidney Dis 2000;35:629-37.
14. Parsons DS, Harris DC. A review of quality of life in chronic renal failure. Pharmacoeconomics 1997;12(2 Pt 1):140-60.
15. McGregor DO, Buttimore AL, Lynn KL, Nicholls MG, Jardine DL. A comparative study of blood pressure control with short in-center versus long home hemodialysis. Blood Purif 2001;19:293-300.
16. Arkouche W, Traeger J, Delawari E, Sibai-Galland R, Abdullah E, Galland R, et al. Twenty-five years of experience with out-center hemodialysis. Kidney Int 1999;56:2269-75.
17. Bremer BA, McClauley CR, Wrona RM, Johnson JP. Quality of life in end-stage renal disease: A reexamination. Am J Kidney Dis 1989;13:200-9.
18. Capelli JP, Camiscioli TC, Vallorani RD, Bobeck JD. Comparative analysis of survival on home hemodialysis, in-center hemodialysis and chronic peritoneal dialysis (CAPD-IPD) therapies. Dial Transplant 1985;14:38-52.
19. Courts NF, Boyette BG. Psychosocial adjustment of males on three types of dialysis. Clin Nurs Res 1998;7:47-63.
20. Covic A. Impact of the renal replacement therapy (RRT) modality on autonomic nervous system function. Nephrol Dial Transplant 1998;13:A112.
21. Hart LG, Evans RW. The functional status of ESRD patients as measured by the Sickness Impact Profile. J Chronic Dis 1987;40(Suppl 1):117S-136S.
22. Hellerstedt WL, Johnson WJ, Ascher N, Kjellstrand CM, Knutson R, Shapiro FL, et al. Survival rates of 2,728 patients with end-stage renal disease. Mayo Clin Proc 1984;59:776-83.
23. Livesley WJ. Factors associated with psychiatric symptoms in patients undergoing chronic hemodialysis. Can J Psychiatry 1981;26:562-6.
24. Mailloux LU, Kapikian N, Napolitano B, Mossey RT, Bellucci AG. Home hemodialysis: Patient outcomes during a 24-year period of time from 1970 through 1993. Adv Ren Replace Ther 1996;3:112-19.
25. McGee MG. Familial response to chronic illness: The impact of home versus hospital dialysis. J Am Assoc Nephrol Nurses Tech 1981;8:9-12.
26. Price JD, Ashby KM, Reeve CE. Results of 12 years' treatment of chronic renal failure by dialysis and transplantation. Can Med Assoc J 1978;118:263-6.
27. Reichwald-Klugger E, Tieben-Heibert A, Korn R, Stein L, Weck K, Maiwald G, et al. Psychosocial adaptation of children and their parents to hospital and home hemodialysis. Int J Pediatr Nephrol 1984;5:45-52.
28. Rubin J, Hsu H, Bower J. Survival on dialysis therapy: One center's experience. Am J Med Sci 1989;297:80-90.
29. Schreiber WK, Huber W. Psychological situation of dialysis patients and their families. Dial Transplant 1985;14:696-8.
30. Soskolne V, De Nour AK. Psychosocial adjustment of home hemodialysis, continuous ambulatory peritoneal dialysis and hospital dialysis patients and their spouses. Nephron 1987;47:266-73.
31. Westlie L, Umen A, Nestrud S, Kjellstrand CM. Mortality, morbidity, and life satisfaction in the very old dialysis patient. Trans Am Soc Artif Intern Organs 1984;30:21-30.
32. Williams GW, Weller JM, Ferguson CW, Forsythe SB, Wu SC. Survival of endstage renal disease patients: Age-adjusted differences in treatment outcomes. Kidney Int 1983;24:691-3.
33. Woods JD, Port FK, Stannard D, Blagg CR, Held PJ. Comparison of mortality with home hemodialysis and center hemodialysis: A national study. Kidney Int 1996;49:1464-70.
34. Churchill DN. The effect of treatment modality on the quality of life for patients with end-stage renal disease. In: Khanna R, editor. Advances in CAPD. Toronto: Peritoneal Dialysis Bulletin Inc; 1988. p. 63-5.
35. Freeman RM, Richards CJ. Studies on sulfate in end-stage renal disease. Kidney Int 1979;15:167-75.
36. Page S, Weisberg MG. Marital and family characteristics of home and hospital dialysis patients. Loss Grief Care 1991;5(1-2):33-45.
37. Piltz-Kirkby M, Fox MA. Support systems as a factor in hemodialysis@mellip;home hemodialysis over in-center hemodialysis. Nephrol Nurse 1982;4:19-26.
38. Evans RW, Manninen DL, Garrison LP Jr, Hart LG, Blagg CR, Gutman RA, et al. The quality of life of patients with end-stage renal disease. N Engl J Med 1985;312:553-9.
39. Disney APS, editor. Australian and New Zealand Combined Dialysis and Transplant Registry (ANZDATA). Annual Report. Adelaide: ANZDATA; 1994.
40. Morris PL, Jones B. Transplantation versus dialysis: A study of quality of life. Transplant Proc 1988;20:23-6.
41. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275-83.
42. De Wit GA. Economic evaluation of end stage renal disease treatment. Health Policy 1998;44:215-32.
43. Peeters P, Rublee D, Just PM, Joseph A. Analysis and interpretation of cost data in dialysis: Review of Western European literature. Health Policy 2000;54:209-27.
44. Goeree R, Manalich J, Grootendorst P, Beecroft ML, Churchill DN. Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin Invest Med 1995;18:455-64.
45. Ting G, Carrie B, Freitas T, Zarghamee S. Global ESRD costs associated with a short daily hemodialysis program in the United States. Home Hemodial Int 1999;3:41-4.
46. Buxton MJ, West RR. Cost-benefit analysis of long-term haemodialysis for chronic renal failure. BMJ 1975;2:376-9.
47. Croxson BE, Ashton T. A cost effectiveness analysis of the treatment of end stage renal failure. N Z Med J 1990;103:171-4.
48. Delano BG, Feinroth MV, Feinroth M, Friedman EA. Home and medical center hemodialysis. Dollar comparison and payback period. JAMA 1981;246:230-2.
49. Garner TI, Dardis R. Cost-effectiveness analysis of end-stage renal disease treatments. Med Care 1987;25:25-34.
50. Kooistra MP, Vos PF. Daily home hemodialysis: Towards a more physiological treatment of patients with ESRD. Semin Dial 1999;12:424-30.
51. Kooistra MP, Vos J, Koomans HA, Vos PF. Daily home haemodialysis in The Netherlands: Effects on metabolic control, haemodynamics, and quality of life. Nephrol Dial Transplant 1998;13:2853-60.
52. Lim TO, Lim YN, Wong HS, Ahmad G, Singam TS, Morad Z, et al. Cost effectiveness evaluation of the Ministry of Health Malaysia dialysis programme. Med J Malaysia 1999;54:442-52.
53. Ludbrook A. A cost-effectiveness analysis of the treatment of chronic renal failure. Appl Econ 1981;13:337-50.
54. Mackenzie P, Mactier RA. Home haemodialysis in the 1990s. Nephrol Dial Transplant 1998;13:1944-8.
55. Pierratos A. Daily hemodialysis. Curr Opin Nephrol Hypertens 2000;9:637-42.
56. Traeger J, Galland R, Arkouche W, Delawari E, Fouque D. Short daily hemodialysis: A four-year experience. Dial Transplant 2001;30:78-86.
57. Stange PV, Sumner AT. Predicting treatment costs and life expectancy for end-stage renal disease. N Engl J Med 1978;298:372-8.
58. Baxter Healthcare Ltd. The Clinical Effectiveness and Cost Effectiveness of Home Versus Hospital Haemodialysis. Submission to the National Institute for Clinical Excellence. Compton, UK: Baxter Healthcare Ltd; 2002 Jan.
59. UK Renal Registry. Report 2001. URL: http://www.renalreg.com
60. Valderrabano F, Berthoux FC, Jones EH, Mehls O. Report on management of renal failure in Europe, XXV, 1994 end stage renal disease and dialysis report. The EDTA-ERA Registry. European Dialysis and Transplant Association-European Renal Association. Nephrol Dial Transplant 1996;11(Suppl 1):2-21.
61. Kirby L, Vale L. Dialysis for end-stage renal disease. Determining a cost-effective approach. Int J Technol Assess Health Care 2001;17:181-9.
62. Mehta D, editor. British National Formulary. London: British Medical Association; Royal Pharmaceutical Society of Great Britain; 2001.
63. The Automobile Association (UK). 2002. URL: http://www.theaa.com
64. NICE. Appraisal of new and existing technologies: Interim guidance for manufacturers and sponsers. 2000. URL: http://server2.nice.org.uk/embcat2.asp?page=oldsite/appraisals/apr_gide.htm